Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far

Anne Clavreul,1,2 Milad Pourbaghi-Masouleh,2,3 Emilie Roger,4 Philippe Menei1,2 1Department of Neurosurgery, CHU, Angers, France; 2CRCINA, INSERM, University of Nantes, University of Angers, Angers, France; 3Division of Drug Delivery and Tissue Engineering, School of Pharmacy, University o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Clavreul A, Pourbaghi-Masouleh M, Roger E, Menei P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	antiangiogenic factors delivery methods glioblastoma Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0a2d800fa252474da15c67fff80cae46
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0a2d800fa252474da15c67fff80cae46
record_format	dspace
spelling	oai:doaj.org-article:0a2d800fa252474da15c67fff80cae462021-12-02T05:40:31ZNanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far1178-2013https://doaj.org/article/0a2d800fa252474da15c67fff80cae462019-04-01T00:00:00Zhttps://www.dovepress.com/nanocarriers-and-nonviral-methods-for-delivering-antiangiogenic-factor-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Anne Clavreul,1,2 Milad Pourbaghi-Masouleh,2,3 Emilie Roger,4 Philippe Menei1,2 1Department of Neurosurgery, CHU, Angers, France; 2CRCINA, INSERM, University of Nantes, University of Angers, Angers, France; 3Division of Drug Delivery and Tissue Engineering, School of Pharmacy, University of Nottingham, Nottingham, UK; 4MINT, INSERM 1066, CNRS 6021, University of Angers, Angers, France Abstract: Angiogenesis, the formation of new blood vessels, is an essential component of glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment. There are several possible reasons for this limited efficacy, including VEGF-independent angiogenesis, induction of tumor invasion, and inefficient antiangiogenic factor delivery to the tumor. Efforts have been made to overcome these limitations by identifying new angiogenesis inhibitors that target angiogenesis through different mechanisms of action without inducing tumor invasion, and through the development of viral and nonviral delivery methods to improve antiangiogenic activity. Herein, we describe the nonviral methods, including convection-enhanced delivery devices, implantable polymer devices, nanocarriers, and cellular vehicles, to deliver antiangiogenic factors. We focus on those evaluated in intracranial (orthotopic) animal models of GB, the most relevant models of this disease, as they reproduce the clinical scenario of tumor progression and therapy response encountered in GB patients. Keywords: antiangiogenic factors, delivery methods, glioblastoma, convection-enhanced delivery devices, implantable polymer devices, nanocarriers, cellular vehicles  Clavreul APourbaghi-Masouleh MRoger EMenei PDove Medical Pressarticleantiangiogenic factorsdelivery methodsglioblastomaMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 2497-2513 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	antiangiogenic factors delivery methods glioblastoma Medicine (General) R5-920
spellingShingle	antiangiogenic factors delivery methods glioblastoma Medicine (General) R5-920 Clavreul A Pourbaghi-Masouleh M Roger E Menei P Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
description	Anne Clavreul,1,2 Milad Pourbaghi-Masouleh,2,3 Emilie Roger,4 Philippe Menei1,2 1Department of Neurosurgery, CHU, Angers, France; 2CRCINA, INSERM, University of Nantes, University of Angers, Angers, France; 3Division of Drug Delivery and Tissue Engineering, School of Pharmacy, University of Nottingham, Nottingham, UK; 4MINT, INSERM 1066, CNRS 6021, University of Angers, Angers, France Abstract: Angiogenesis, the formation of new blood vessels, is an essential component of glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment. There are several possible reasons for this limited efficacy, including VEGF-independent angiogenesis, induction of tumor invasion, and inefficient antiangiogenic factor delivery to the tumor. Efforts have been made to overcome these limitations by identifying new angiogenesis inhibitors that target angiogenesis through different mechanisms of action without inducing tumor invasion, and through the development of viral and nonviral delivery methods to improve antiangiogenic activity. Herein, we describe the nonviral methods, including convection-enhanced delivery devices, implantable polymer devices, nanocarriers, and cellular vehicles, to deliver antiangiogenic factors. We focus on those evaluated in intracranial (orthotopic) animal models of GB, the most relevant models of this disease, as they reproduce the clinical scenario of tumor progression and therapy response encountered in GB patients. Keywords: antiangiogenic factors, delivery methods, glioblastoma, convection-enhanced delivery devices, implantable polymer devices, nanocarriers, cellular vehicles
format	article
author	Clavreul A Pourbaghi-Masouleh M Roger E Menei P
author_facet	Clavreul A Pourbaghi-Masouleh M Roger E Menei P
author_sort	Clavreul A
title	Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
title_short	Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
title_full	Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
title_fullStr	Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
title_full_unstemmed	Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
title_sort	nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/0a2d800fa252474da15c67fff80cae46
work_keys_str_mv	AT clavreula nanocarriersandnonviralmethodsfordeliveringantiangiogenicfactorsforglioblastomatherapythestorysofar AT pourbaghimasoulehm nanocarriersandnonviralmethodsfordeliveringantiangiogenicfactorsforglioblastomatherapythestorysofar AT rogere nanocarriersandnonviralmethodsfordeliveringantiangiogenicfactorsforglioblastomatherapythestorysofar AT meneip nanocarriersandnonviralmethodsfordeliveringantiangiogenicfactorsforglioblastomatherapythestorysofar
_version_	1718400274660327424

Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far

Ejemplares similares